Walleye Capital LLC Viridian Therapeutics, Inc.\De Put Options Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$17.09 - $23.82 $34,180 - $47,640	-2,000 Reduced 35.71%	3,600 $63,000
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $56,711 - $114,750	5,100 Added 1020.0%	5,600 $121,000
Q3 2023 Nov 14, 2023	BUY	$15.16 - $24.7 $3,032 - $4,940	200 Added 66.67%	500 $7,000
Q2 2023 Aug 14, 2023	SELL	$22.57 - $29.67 $103,822 - $136,482	-4,600 Reduced 93.88%	300 $7,000
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $50,080 - $75,200	2,000 Added 68.97%	4,900 $124,000
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $26,292 - $41,636	1,400 Added 93.33%	2,900 $84,000
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $16,049 - $38,250	1,500 New	1,500 $31,000

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $806M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.